Clinical trials: Adult ADHD
Attention Deficit Hyperactivity Disorder
Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder
This study tests the effects of an investigational antipsychotic drug (called OPC-34712) in adults with attention deficit hyperactivity disorder (ADHD) when taken with an approved stimulant medication to explore a possible impact…
- Trial name
- STEP-A (NCT01074294)
- Testing
- OPDC-34712, Stimulant Therapy
- Where
- 35 sites in United States
- Volunteers
- 740 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Attention Deficit Hyperactivity Disorder
Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) With Atomoxetine in Young Adults and Its Effects on Functional Outcomes
This study will evaluate atomoxetine's efficacy in treating attention-deficit/hyperactivity disorder (ADHD) symptoms and atomoxetine's effect on functional outcomes in young adults.
- Trial name
- NCT00510276
- Testing
- Atomoxetine hydrochloride
- Where
- 29 sites in United States, Puerto Rico
- Volunteers
- 445 people
- Sponsor
- Eli Lilly and Company
Attention-Deficit/Hyperactivity Disorder
Safety and Efficacy of Vyvanse in Adults With Attention-Deficit/Hyperactivity Disorder
The primary objective of this study is to evaluate the maintenance of efficacy, as measured by Adult ADHD Rating Scale with Prompts (Adult ADHD-RS with prompts) and Clinical Global Impression - Severity (CGI-S) scores, through a…
- Trial name
- NCT00877487
- Testing
- SPD489 (Lisdexamfetamine dimesylate)
- Where
- 55 sites in United States
- Volunteers
- 123 people
- Sponsor
- Shire
Attention Deficit Hyperactivity Disorder
A Study to Test Different Ways to Measure the Effect of Atomoxetine on Impulsive Behavior in Young Adults With Attention Deficit Hyperactivity Disorder (ADHD)
The primary objectives are to investigate the effect of atomoxetine on impulsivity after single dose and at steady state measured by the total score of Barrett Impulsiveness Scale version 11 (BIS-11) and Short Urgency…
- Trial name
- NCT05278104
- Testing
- Zentiva®
- Where
- 5 sites in Germany
- Volunteers
- 63 people
- Sponsor
- Boehringer Ingelheim
Attention-Deficit/Hyperactivity Disorder, ADHD
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
The safety and efficacy of multiple dosages of TD-9855, administered once daily, will be evaluated in adult males with ADHD.
- Trial name
- NCT01458340
- Testing
- TD-9855
- Where
- 17 sites in United States
- Volunteers
- 295 people
- Sponsor
- Theravance Biopharma
Attention Deficit Hyperactivity Disorder
A Study to Evaluate the Efficacy and Safety of Two Doses of PF-03654746 in Adults With Attention Deficit Hyperactivity Disorder (ADHD).
The purpose of this study is to determine whether PF-03654746 is effective in the treatment of Adult Attention Deficit Hyperactivity Disorder (ADHD).
- Trial name
- NCT00531752
- Testing
- PF-03654746
- Where
- 7 sites in United States
- Volunteers
- 66 people
- Sponsor
- Pfizer
Attention Deficit Hyperactivity Disorder
A Long Term Follow-Up Study for Asian Adult Patients With Attention Deficit Hyperactivity Disorder
The purpose of this study is to assess long-term safety and tolerability in adult patients who have completed a previous atomoxetine study.
- Trial name
- NCT00969618
- Testing
- Atomoxetine
- Where
- 12 sites in Japan
- Volunteers
- 211 people
- Sponsor
- Eli Lilly and Company
Attention-Deficit/Hyperactivity Disorder (ADHD)
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD
This study will evaluate the efficacy and safety of SPN-812 (Viloxazine extended-release capsules; 200-600 mg) in adults 18-65 years of age with Attention-Deficit/Hyperactivity Disorder (ADHD).
- Trial name
- NCT04016779
- Testing
- SPN-812
- Where
- 37 sites in United States
- Volunteers
- 374 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Attention Deficit Hyperactivity Disorder
Safety and Efficacy of GTS21 in Adults With Attention-deficit Hyperactivity Disorder
This study will be a randomized, double-blind, placebo-controlled crossover study to assess the effects of GTS21 (25 mg three times a day (tid), 75 mg tid, 150 mg tid) compared to placebo in non-smoking adults aged 18-55 with a…
- Trial name
- NCT00419445
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- CoMentis
Attention-Deficit/Hyperactivity Disorder (ADHD)
Evaluation of Immediate-Release Viloxazine in Adults With ADHD
This will be a randomized, double-blind, placebo-controlled, parallel group, safety and tolerability study in adults with ADHD. The target subjects are healthy male or female adults aged 18 to 64 years, inclusive, with a…
- Trial name
- NCT01107496
- Testing
- IR Viloxazine
- Where
- 4 sites in United States
- Volunteers
- 52 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
ADHD
PRC-063 Adult Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
This is a randomized, double-blind, parallel group, placebo-controlled, dose optimized, phase 3 study to evaluate the safety and efficacy of PRC-063 in the treatment of ADHD in adults
- Trial name
- NCT03618030
- Testing
- PRC-063 oral capsules
- Where
- 8 sites in United States
- Volunteers
- 288 people
- Sponsor
- Purdue Pharma, Canada
ADHD
A Novel Device for the Management of ADHD
This is a 2-months study, where eligible ADHD adult participants will be provided with personalized VIZO glasses.
- Trial name
- NCT05777785
- Testing
- VIZO Glasses
- Where
- Israel
- Volunteers
- 108 people
- Sponsor
- VIZO Specs Ltd
Attention-Deficit Hyperactivity Disorder (ADHD)
PDC-1421 Treatment in Adult Patients With ADHD
Part II is a double-blind, randomized, parallel-group, placebo-controlled study. The primary objective of this trial is to determine the effective doses and treatment period of PDC-1421 Capsule in subjects with ADHD.
- Trial name
- NCT05202327
- Testing
- PDC-1421 Capsule
- Where
- 6 sites in United States, Taiwan
- Volunteers
- 99 people
- Sponsor
- BioLite, Inc.
Attention Deficit Disorder With Hyperactivity
Adult Study / OROS Methylphenidate Hydrochloride (HCL) (OROS MPH) in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to compare the ADHD symptom response of adults with ADHD treated with OROS MPH to those treated with placebo.
- Trial name
- NCT00937040
- Testing
- OROS MPH, OROS MPH Tablets
- Volunteers
- 357 people
- Sponsor
- Ortho-McNeil Janssen Scientific Affairs, LLC
ADHD
CTx-1301 Comparative Bioavailability Study
The primary purpose of this study is to compare the bioavailability of CTx-1301 (dexmethylphenidate) to the registered listed drug, Focalin XR and to evaluate dose proportionality of CTx-1301.
- Trial name
- NCT04138498
- Testing
- Dexmethylphenidate 5 Mg Oral Capsule, Extended Release, Dexmethylphenidate 6.25 mg Tablet, Dexmethylphenidate 40 Mg Oral Capsule, Extended Release
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Cingulate Therapeutics
ADHD
The Efficacy and Safety of PRC-063 in Adult ADHD Patients
The purpose of this randomized, placebo-controlled, double-blind, parallel group study is to evaluate the clinical efficacy and safety of PRC-063 in adults with ADHD
- Trial name
- NCT02139124
- Testing
- PRC-063 25 mg, PRC-063 45 mg, PRC-063 70 mg
- Where
- 38 sites in United States, Canada
- Volunteers
- 375 people
- Sponsor
- Rhodes Pharmaceuticals, L.P.
ADHD, Attention-Deficit/Hyperactivity Disorder, Predominantly Inattentive Type
A 6 Week Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD ( Attention Deficit/Hyperactivity )
This study is a multisite, randomized, double-blind, placebo-controlled, phase 2/3 study of MG01CI (1400 mg daily) for 6 weeks compared with placebo in a 1:1 ratio of 300 adults with ADHD.
- Trial name
- NCT02059642
- Testing
- MG01CI (1400 mg)
- Where
- 20 sites in United States, Israel
- Volunteers
- 300 people
- Sponsor
- Alcobra Ltd.
Attention Deficit Hyperactivity Disorder, Attention Deficit Disorders With Hyperactivity
An Open-label Study of NRP104 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to assess the long-term safety and efficacy of three NRP104 doses of 30 mg, 50 mg, or 70 mg, administered at the same time daily, in the treatment of adults with ADHD.
- Conditions
- Attention Deficit Hyperactivity Disorder, Attention Deficit Disorders With Hyperactivity, Attention Deficit Hyperactivity Disorders
- Trial name
- NCT00337285
- Testing
- Vyvanse (lisdexamfetamine dimesylate), NRP104
- Where
- 45 sites in United States
- Volunteers
- 349 people
- Sponsor
- New River Pharmaceuticals
Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder
A Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder
This study evaluated the long-term safety and tolerability of centanafadine sustained-release (SR) tablets, administered twice daily (BID) in the treatment of adults with attention deficit hyperactivity disorder (ADHD).
- Trial name
- NCT03605849
- Testing
- Centanafadine SR
- Where
- United States
- Volunteers
- 662 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Attention Deficit/Hyperactivity Disorder
Open-label Extension Evaluating Methylphenidate Hydrochloride Extended Release in Adults With Attention Deficit/Hyperactivity Disorder
This study will evaluate the long-term safety of methylphenidate hydrochloride extended release in adults with attention deficit/hyperactivity disorder
- Trial name
- NCT01338818
- Testing
- Ritalin LA (methylphenidate hydrochloride extended release)
- Where
- 48 sites in United States, Belgium and 4 more
- Volunteers
- 299 people
- Sponsor
- Novartis Pharmaceuticals